Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis

Abstract

Glucocorticoids are standard therapy for induction of response in proliferative lupus nephritis. However, the optimal duration of glucocorticoid therapy is uncertain. We surveyed physicians who treat lupus nephritis regarding their use of glucocorticoids in proliferative lupus nephritis after induction of response and regarding factors associated with different practice patterns. We administered a questionnaire of standardized cases assessing glucocorticoid use after induction of response to specialists with expertise in proliferative lupus nephritis. We examined the association between continuation of glucocorticoids and patient and physician characteristics. Of 90 invited participants, 72 (80%) responded. A total of 24 (33%) respondents attempted to discontinue glucocorticoids in all scenarios, 21 (29%) continued glucocorticoids in all scenarios, and 27 (38%) attempted to discontinue in some scenarios but not others. Responses varied according to the physician group (p < 0.001) and by years in practice (p < 0.001). Of those who discontinued glucocorticoids in selected scenarios, 15/27 (55%) were influenced by the characteristics of the induction of response, 16/27 (59%) by past lupus history, and 9/27 (33%) by the tolerance and use of immunosuppression. We conclude that glucocorticoid therapy after induction of response in proliferative lupus nephritis is varied. This variability likely represents clinical equipoise. A randomized trial evaluating the effect of glucocorticoid use after induction of response is warranted.

Keywords

glucocorticoids nephritis renal lupus

Get full access to this article

View all access options for this article.

References

Baldwin DS , Lowenstein J. , Rothfield NF , Gallo G. , McCluskey RT The clinical course of the proliferative and membranous forms of lupus nephritis . Ann Intern Med 1970; 73: 929-942.

Nossent JC , Bronsveld W. , Swaak AJ Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989; 48: 810-816.

Illei GG , Takada K. , Parkin D. , et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies . Arthritis Rheum 2002; 46: 995-1002.

Zonana-Nacach A. , Barr SG , Magder LS , Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.

Gourley MF , Austin HA III , Scott D. , et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.

Yee CS , Gordon C. , Dostal C. , et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis 2004; 63: 525-529.

Austin HA III , Klippel JH , Balow JE , et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.

Bertsias G. , Ioannidis JP , Boletis J. , et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.

Hoes JN , Jacobs JWG , Boers M. , et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-1567.

10.

Moroni G. , Quaglini S. , Maccario M. , Banfi G. , Ponticelli C. ‘‘Nephritic flares’’ are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50: 2047-2053.

11.

Ginzler EM , Aranow C. Prevention and treatment of adverse effects of corticosteroids in systemic lupus erythematosus. Baillieres Clin Rheumatol 1998; 12: 495-510.

12.

Davis JM III , Maradit KH , Crowson CS , et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 2007; 56: 820-30.

13.

Eastell R. , Devogelaer JP , Peel NF , et al. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 2000; 11: 331-337.

14.

McDougall R. , Sibley J. , Haga M. , Russell A. Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls . J Rheumatol 1994; 21: 1207-1213.

15.

Mitchell DM , Spitz PW , Young DY , et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-714.

16.

Roger L. Serious adverse events with low-dose, long-term corticosteroid therapy in rheumatoid arthritis. Am J Med 1995; 99: 692-694.

17.

Saag KG , Koehnke R. , Caldwell JR , et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-123.

18.

Wolfe F. , Mitchell DM , Sibley JT , et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-494.

19.

Manzi S. , Selzer F. , Sutton-Tyrrell K. , et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 51-60.

20.

Lima DS , Sato EI , Lima VC , et al. Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 292-297.

21.

Asanuma Y. , Oeser A. , Shintani AK , et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2407-2415.

22.

Roman MJ , Shanker BA , Davis A. , et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-2406.

23.

Asanuma Y. , Chung CP , Oeser A. , et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors . J Rheumatol 2006; 33: 539-545.

24.

Richter B. , Neises G. , Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin North Am 2002 ; 31: 751-778.

25.

Walsh M. , Merkel PA , Mahr A. , Jayne D.

A systematic review and meta-analysis of relapses in ANCA-Associated Vasculitis (AAV): what is the effect of low-dose corticosteroids?

J Am Soc Nephrol 2007; 19: PO919.

26.

Kirwan JR The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333: 142-146.

27.

da Silva JA , Jacobs JW , Kirwan JR , et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-293.

28.

Capell HA , Madhok R. , Hunter JA , et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63: 797-803.

29.

Hricik DE , O’Toole MA , Schulak JA , Herson J. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-1305.

30.

Kasiske BL , Chakkera HA , Louis TA , Ma JZ A meta-analysis of immunosuppression withdrawal trials in renal transplantation . J Am Soc Nephrol 2000; 11: 1910-1917.

31.

Pascual J. , Quereda C. , Zamora J. , Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548-1556.